Search

Your search keyword '"C. J. van Loenhout"' showing total 2 results
Start Over Author "C. J. van Loenhout"
2 results on '"C. J. van Loenhout"'

1. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Author

F. Terhegggen, G. P. Bootsma, Hans M. Westgeest, Jessica S.W. Borgers, Daphne W. Dumoulin, M. Cloos, J. W. G. van Putten, John B. A. G. Haanen, C. J. van Loenhout, W. K. de Jong, I. Houtenbos, G. A. Cirkel, Otto Visser, J. C. Drooger, R. A.W. van de Wetering, T. J.N. Hiltermann, B. van den Borne, F. S. van der Meer, V. J.A.A. Nuij, Esther Oomen-de Hoop, C. H. van der Leest, Hanneke W. M. van Laarhoven, A. Becker-Commissaris, S. C.van t. Westeinde, A. P. Hamberg, L. van Leeuwen, A. S.R. van Lindert, B. W. Bouter, Rutger H. T. Koornstra, F. J. Borm, C. H. Rikers, E. A. Kastelijn, B. M.J. Scholtes, Y. Klaver, E. J.M. Siemerink, D. M. van Diepen, A. L. Peerdeman, Mieke J. Aarts, K. H. Herbschleb, V. E.M. van den Boogaart, Karijn P M Suijkerbuijk, G. Douma, S. D. Bakker, Karlijn de Joode, A. J. Staal, M. P.L. Bard, J. A. Stigt, C. C.M. Pitz, L. J. C. van Warmerdam, E. Looysen, Laurens V. Beerepoot, P. Brocken, C. R. van Rooijen, N. J.M. Claessens, Haiko J. Bloemendal, A.J. van de Wouw, Astrid A M van der Veldt, E. Citgez, Franchette W P J van den Berkmortel, M. Youssef, E. J. Geraedts, Nico G.J. van Diemen, G. L. Veurink, E. J. Libourel, N. P. Barlo, Elisabeth G.E. de Vries, J.W.B. de Groot, Anne-Marie C. Dingemans, W. H. van Geffen, G. J.M. Herder, Pim G N J Mutsaers, L. Strobbe, Jolien Tol, R. Heller, L. M. Faber, B. Franken, Lizza E.L. Hendriks, Mathilde Jalving, O. C.J. Schuurbiers-Siebers, B. C.M. Haberkorn, M. A. Tiemessen, M. Slingerland, Oncology, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, APH - Personalized Medicine, APH - Methodology, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Medical Oncology, Pulmonary Medicine, Health Technology Assessment (HTA), Hematology, Rotterdam School of Management, Radiology & Nuclear Medicine, Econometrics, Internal Medicine, Erasmus MC other, Gastroenterology & Hepatology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON), and Translational Immunology Groningen (TRIGR)

Subjects
0301 basic medicine, Oncology, Male, medicine.medical_specialty, Cancer Research, Coronavirus disease 2019 (COVID-19), Subgroup analysis, Malignancy, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Risk Factors, Internal medicine, Neoplasms, Pandemic, medicine, Humans, Registries, Lung cancer, Pandemics, Original Research, Aged, Netherlands, Cancer, business.industry, Incidence, COVID-19, Middle Aged, medicine.disease, Vaccination, Coronavirus, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Cancer treatment, Female, business, Cohort study, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Aim of the study Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19. Methods This observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients’ characteristics, cancer diagnosis, and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible. Results Between March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age ≥65 years (p, Highlights • Patients with cancer might have an increased risk for severe outcome of COVID-19. • This nationwide study investigated risk factors for fatal outcome of COVID-19. • Among 442 registered patients with cancer, 32.3% of patients died of COVID-19. • Haematological malignancy and lung cancer increased the risk of fatal outcome. • These results can guide treatment and vaccination decisions in patients with cancer.

Published
2020

2. [A rare form of obstructive pulmonary disease]

Author

C J, van Loenhout, M A, den Bakker, M S, van Wijsenbeek, R A S, Hoek, and P Th W, van Hal

Subjects
Adult, Diagnosis, Differential, Lung Neoplasms, Biopsy, Humans, Female, Lung Diseases, Obstructive, Lymphangioleiomyomatosis, Tomography, X-Ray Computed, Lung, Respiratory Function Tests
Abstract

Lymphangioleiomyomatosis (LAM) is characterised by progressive dyspnoea, spontaneous pneumothorax and cystic pulmonary destruction. The disease may show similarities with emphysema clinically, radiologically and on lung function tests.A 44-year-old woman was referred for lung transplantation because of a 6-year history of dyspnoea and severe obstructive pulmonary function disorder with decreased diffusion capacity. Both her relatively young age and the fact that she had never smoked made us doubt the diagnosis 'COPD'. The pulmonary cysts seen on high-resolution CT (HRCT) suggested LAM. This was confirmed when we revised a pulmonary biopsy that had previously been performed.CT investigation should be carried out in patients with severe obstructive pulmonary disease without a risk profile appropriate for COPD. Diffuse, homogenous cysts on CT scan can indicate LAM, particularly in women. Conflict of interest and financial support: none declared.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results